Catalyst Biosciences was down to five employees in March, and the biotech needed to do something after two rounds of layoffs, a nixed collaboration and a culling of its hemophilia program. In came Vertex, with $60 million to buy up the South San Francisco biotech’s preclinical complement drugs, which target the system that bridges the … Continue reading After $60M Vertex deal, group of Catalyst shareholders claims biotech could’ve sold assets three years ago